Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET

Company Participants

Cristi Barnett - Corporate Communications and Investor Relations
Gilmore O’Neill - Chief Executive Officer
Baisong Mei - Chief Medical Officer
Erick Lucera - Chief Financial Officer
Linda Burkly - Chief Scientific Officer
Caren Deardorf - Chief Commercial and Strategy Officer

Conference Call Participants

Jack Allen - Baird
Samantha Semenkow - Citi
Eric Schmidt - Cantor Fitzgerald
Terence Flynn - Morgan Stanley
Gena Wang - Barclays
Mary Kate Davis - Bank of America
Brian Cheng - JPMorgan
Dae Gon Ha - Stifel
Luca Issi - RBC Capital
Phil Nadeau - TD Cowen
Yanan Zhu - Wells Fargo Securities

Operator

Good morning and welcome to the Editas Medicine’s Second Quarter 2024 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company’s request.

I would now like to turn the call over to Cristi Barnett, Corporate Communications and Investor Relations at Editas Medicine.

Cristi Barnett

Thank you, Britney. Good morning, everyone and welcome to our second quarter 2024 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today’s call will be available in the Investors section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A.

As a reminder, various remarks that we make during this call about the company’s future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is on file with the SEC, as updated by our subsequent filings.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change.

Now, I will turn the call over to our CEO, Gilmore O’Neill.

Gilmore O’Neill

Thanks, Cristi and good morning everyone. Thank you for joining us today on Editas’ second quarter 2024 earnings call. With me today are four members of the Editas executive team, our Chief Medical Officer, Baisong Mei; our Chief Financial Officer, Erick Lucera; our Chief Scientific Officer, Linda Burkly; and our Chief Commercial and Strategy Officer, Caren Deardorf.